MARTINSRIED/MUNICH, Germany & PRINCETON, N.J., Oct 27, 2008 (BUSINESS WIRE) -- GPC Biotech AG (GPCB:
GPCB 0.72, +0.06, +9.7%) today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, were presented at the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in a poster entitled, "RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models," (Abstract #578). The data presented demonstrate that the RGB-286638 small molecule has potent activity against chronic myeloid leukemia (CML) in in vivo models that are resistant to imatinib (Gleevec(R) and to dasatinib (Sprycel(R), the current standards of care for treating this form of cancer. Additionally, RGB-286638 has been shown in vitro to be active against a number of families of protein kinases that are important for the proliferation of cancer cells. RGB-286638 is expected to enter Phase 1 clinical testing this year.
